Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-19
2006-09-19
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S016700, C514S017400, C530S326000, C530S327000, C530S328000, C530S329000
Reexamination Certificate
active
07109170
ABSTRACT:
Novel polypeptides or derivatives comprising the factor VIIIa binding site on factor IXa are disclosed. The novel polypeptides or derivatives have anti-coagulation activity. Nucleic acids encoding those polypeptides are also disclosed. Methods for identifying an agent having anti-coagulation activity are also disclosed. These methods comprise determining whether the agent displaces the polypeptide or derivative from its factor VIIIa binding site. The agent identified in these methods is also useful in methods for treating a patient to prevent thrombosis. The treatment methods comprise administration of the agent to the patient. Additional methods are also disclosed for treating a patient to prevent thrombosis, comprising treating the patient with a polypeptide or derivative comprising the factor VIIIa binding site on factor IXa. Methods of preventing coagulation in a blood sample are also disclosed, comprising adding the polypeptides or derivatives described above to the blood sample. Methods of detecting factor VIIIa in a sample are also disclosed. Those methods comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding factor VIIIa from the sample.
REFERENCES:
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5639863 (1997-06-01), Dan
patent: 5914110 (1999-06-01), Holmes et al.
patent: 5932706 (1999-08-01), Mertens et al.
patent: 6624289 (2003-09-01), Bajaj
patent: WO 93/09804 (1993-05-01), None
patent: WO 94/25482 (1994-11-01), None
patent: WO9526979 (1995-10-01), None
Mathur et al., Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa, J. Biol. Chem., 1999, 274(26): 18477-18486.
Yoshitake et al., Nucleotide sequence of the gene for human factor IX (antihemophilic factor B), Biochemistry, 1985, 24: 3736-3750.
DiScipio et al., Activation of human factor IX (Christmas factor), J. Clin. Invest., 1978, 61: 1528-1538.
Davie et al., The coagulation cascade: initiation, maintenance, and regulation, Biochemistry, 1991, 30: 10363-10370.
Brandstetter et al., X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B., Proc. Natl. Acad. Sci. USA, 1995, 92: 9796-9800.
Banner et al., The crystal structure of the complex of blood coagulation factor Vila with soluable tissue factor, Nature, 1996, 380: 41-46.
Sabharwal et al., Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding, J. Biol. Chem., 1997, 272: 22037-22045.
Rao et al., The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions, Cell, 1995, 82: 131-141.
Bajaj et al., Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain, Proc. Natl. Acad. Sci. USA; 1992, 89: 152-156.
Freedman et al., Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX, J. Biol. Chem., 1996, 271: 16227-16236.
Zhong et al., First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa, Proc. Natl. Acad. Sci. USA, 1994, 91: 3574-3578.
Lenting et al., Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding, J. Biol. Chem., 1996, 271: 25332-25337.
Ahmed et al., The role of the second growth-factor domain of human factor IXa in binding to platelets and in factor-X activation, Biochem. J., 1995, 310: 427-431.
Astermark et al., The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation, J. Biol. Chem., 1994, 269: 3682-3689.
O'Brien et al., Localization of factor IXa and factor VIIIa interactive sites, J. Biol. Chem., 1995, 270: 27087-27092.
Bajaj et al., Human factor IX and factor IXa, Methods Enzymol, 1993, 222: 96-128.
Mathur et al., Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipids, and factor X, J. Biol. Chem., 1997, 272: 23418-23426.
Hamaguchi et al., The role of amino-terminal residues of the heavy chain of factor IXa in the binding of its cofactor, factor VIIIa, Blood, 1994, 84: 1837-1842.
Ripka et al., Peptidomimetic design, Current Opin. Chem. Biol., 1998, 2(4): 441-452.
Wood et al., Expression of active human factor VIII from recombinant DNA clones, Nature, 1984, 312: 330-337.
Vehar et al., Structure of human factor VIII, Nature, 1984, 312: 337-342.
Bajaj et al., A simplified procedure for purification of human prothrombin, factor IX and factor X, Prep. Biochem., 1981, 11: 397-412.
Zhong and Bajaj, A PCR-based method for site-specific domain replacement that does not require restriction recognition sequences, Biotechniques, 1993, 15: 874-878.
Usharani et al., Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-evidence for defects affecting the latent catalytic site, J. Clin. Invest., 1985, 75: 76-83.
Link and Castellino, The activation of bovine factor X by bovine factor Xa, Arch. Biochem. Biophys., 1982, 215: 215-221.
Van Dieijen et al., The role of phospholipids and factor VIIIa in the activation of bovine factor X, J. Biol. Chem. 1981, 256: 3433-3442.
Fay and Koshibu, The A2 subunit of factor VIIIa modulates the active site of factor IXa, J. Biol. Chem., 1998, 273: 19049-19054.
Krishnaswamy, The interaction of human factor VIIa with tissue factor, J. Biol. Chem., 1992, 267: 23696-23706.
Halfman, Concentrations of binding protein and labeled analyte that are appropriate for measuring at any analyte concentration range in radioimmunoassays, Meth. Enzymol., 1981, 74: 481-508.
Bylund and Toews, Radioligand binding methods: practical guide and tips, Am. J. Physiol., 1993, 265: L421-L42.
Rees et al., The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor XI, EMBO J., 1988, 7: 2053-2061.
Hughes et al., Tyrosine 69 of the first epidermal growth factor-like domain human factor IX is essential for clotting activity, J. Biol. Chem., 1993, 268: 17727-17733.
Frazier et al., Mapping of monoclonal antibodies to human factor IX, Blood, 1989, 74: 971-977.
Ludwig et al., Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX, Blood, 1992, 79: 1225-1232.
Giannelli et al., Haemophilia B: database of point mutations and short additions and deletions—eighth edition, Nucleic Acids Res., 1998, 26: 265-268.
Mather et al., The 2.8 A crystal structure of Gla-domainless activated protein C, EMBO J., 1996, 15: 6822-6831.
Bajaj et al., Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells and cardiac myocytes, Thrombos. Haemostas, 1999, 82: 1663-1672.
Chang et al., Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity, J. Biol. Chem., 1998, 273: 12089-12094.
Lin et al., Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells, J. Biol. Chem., 1990, 265: 144-150.
Chang et al., Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B, J. Clin. Invest., 1997, 100: 886-892.
Spitzer et al., Factor IX Hollywood: substitution of Pro55 by Ala in the first epidermal growth factor-like domain, Blood, 1990, 76: 1530-1537.
McCord et al., Characterization of the functional defect n factor IX Alabama, J. Biol. Chem., 1990, 265: 10250-10254.
Christophe et al., Blood coagulation f
Bajaj Paul S.
Schmidt Amy E.
Saint Louis University
Thompson & Coburn LLP
Wax Robert A.
LandOfFree
Region of factor IXa protease domain that interacts with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Region of factor IXa protease domain that interacts with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Region of factor IXa protease domain that interacts with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3607186